Ian T. Clark

October 17, 2026

Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.

October 4, 2026

BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.

September 25, 2026

Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.

October 15, 2026

OLMA Joins 12 Healthcare Stocks Moving in Pre-Market. OLMA was among 12 healthcare stocks that moved in Wednesday's pre‑market session, signaling early interest from traders. The move comes while the stock sits near its 52‑week low and a low RSI of 19.1, suggesting it may be oversold. This early activity could reflect new market sentiment or a reaction to broader healthcare sector dynamics.

September 7, 2026

GoodRx Expands Savings Offering With Companion Family Plan for Pets and People. GoodRx has launched a Companion Family Plan that extends its healthcare savings to pets as well as household members. The company is positioning the new offering as a way to bring prescription and care discounts to the entire family, including animals, broadening the appeal of its platform. Separately, a recent market analysis listed GoodRx among stocks viewed as having mixed momentum. The company is already trading near a well-tested support level, providing some technical context around the announcement.

October 13, 2026

AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.